Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30
Drug: biphasic insulin aspart 50

First Posted Date: 2012-06-15

Last Posted Date: 2017-01-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 10

Registration Number: NCT01620424

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2012-06-15

Last Posted Date: 2017-01-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01620463

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: semaglutide

First Posted Date: 2012-06-14

Last Posted Date: 2015-02-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 27

Registration Number: NCT01619345

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: insulin degludec/liraglutide

First Posted Date: 2012-06-13

Last Posted Date: 2017-10-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 435

Registration Number: NCT01618162

Locations: 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey

A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2012-06-13

Last Posted Date: 2018-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 52

Registration Number: NCT01618188

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2012-06-13

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 344

Registration Number: NCT01618214

Locations: 🇨🇳
Novo Nordisk Investigational Site, Hangzhou, Zhejiang, China

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2012-06-12

Last Posted Date: 2017-03-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 451

Registration Number: NCT01617434

Locations: 🇷🇸
Novo Nordisk Investigational Site, Nis, Serbia

Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-06-11

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT01615978

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: NNC0215-0384
Drug: placebo

First Posted Date: 2012-06-05

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT01611688

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: glyburide

First Posted Date: 2012-05-25

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 51

Registration Number: NCT01605773

Locations: 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy